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Background: Neointimal hyperplasia involving smooth muscle cell (SMC) proliferation, migration and extracellular
matrix (ECM) degradation is an important component of atherosclerosis. It develops as a response to vascular injury
after balloon angioplasty and vascular graft placement. Matrix metalloproteinases (MMPs) induce SMC proliferation,
migration and contribute to intimal hyperplasia by degrading ECM. PPARγ agonists inhibit SMC proliferation,
migration and lesion formation. In this study, we aimed to investigate the effects of PPARγ agonist rosiglitazone on
neointimal hyperplasia and gelatinase (MMP-2 and MMP-9) expressions in rabbit carotid anastomosis model.
Methods: New Zealand white rabbits (n = 13, 2.7–3.2 kg) were divided into placebo and treatment groups. Right
carotid artery (CA) was transected and both ends were anastomosed. Treatment group (n = 6) received rosiglitazone
(3 mg/kg/day/p.o.) and placebo group (n = 7) received PBS (phosphate buffered saline, 2.5 ml/kg/day/p.o.) for
4 weeks postoperatively. After the sacrification, right and left CAs were isolated. Morphometric analyses and
immunohistochemical examinations for gelatinases were performed.
Results: Intimal area (0.055 ± 0.005 control vs 0.291 ± 0.020 μm2 anastomosed, p< 0,05) and index (0.117 ± 0.002
control vs 0.574 ± 0.013 anastomosed, p< 0,01) significantly increased in anastomosed arteries compared to control
arteries from placebo group. However, in rosiglitazone-treated group, intimal area (0.291 ± 0.020 PBS vs 0.143 ± 0.027
rosiglitazone, p< 0,05) and index (0.574 ± 0.013 PBS vs 0.263 ± 0.0078 rosiglitazone, p< 0,01) significantly decreased.
Furthermore, gelatinase immunopositivity was found to have significantly increased in anastomosed arteries from
placebo group and decreased with rosiglitazone treatment.
Conclusions: These results suggest that rosiglitazone may prevent neointimal hyperplasia, which is the most
important factor involved in late graft failure, by inhibiting gelatinase enzyme expression.
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Neointimal hyperplasia has a major role in early resten-
osis after surgical interventions such as surgical revascu-
larisation, percutan transluminal angioplasty (PTA) and
stenting [1,2]. It is an early and essential step in the
pathogenesis of atherosclerosis and restenosisis. This step
is characterised by extracellular matrix (ECM) degrad-
ation, and medial vascular smooth muscle cell migration
to intima and their proliferation.* Correspondence: mehmetguzeloglu@hotmail.com
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reproduction in any medium, provided the orMatrix metalloproteases (MMPs) are a family of zinc-
dependent enzymes which induce smooth muscle prolif-
eration and migration by degrading ECM and contribute
to intimal hyperplasia, inflamation and plaque rupture
[3]. Therefore, inhibition of MMPs may be a crucial strat-
egy to reduce the development of intimal hyperplasia.
Peroxisome proliferator-activated receptors (PPARs)
are ligand-activated nuclear receptor family. The three
PPAR isotypes, PPAR-α, PPAR-δ and PPAR-γ modulate
the function of many target genes and participate in the
regulation of vital processes such as inflammation, cell
growth, proliferation, migration and differentiation [4-6].
PPARγ is expressed predominantly in adipose tissue
and it is also present in endothelial cells, smooth muscleral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that the activation of PPARγ inhibited
MMP expression in cultured macrophages and hyperch-
olesterolemic mice [8,9]. This effect contribute to their
antiproliferative effect on SMCs. Indeed, PPARγ agonists
are shown to decrease migration and proliferation of
human and rat vascular SMCs [5]. Similarly, it was
reported that dominant-negative loss of PPARγ function
enhances SMC proliferation, migration, and vascular
remodeling in isolated transgenic mice SMCs [10].
Thiazolidinediones (TZDs), which are widely used in
the treatment of type II diabetics as insulin sensitizers,
are selective activators of PPARγ [11]. Rosiglitazone, a
synthetic PPARγ agonist, was reported to inhibit neointi-
mal hyperplasia in rats after balloon injury, and to
reduce SMC proliferation in rat SMC culture [5,12,13].
Moreover, clinical studies revealed that PPARγ agonists,
rosiglitazone and pioglitazone inhibit development
of neointimal hyperplasia and restenosis after percuta-
neus coronary intervention in diabetic coronary artery
patients [14,15].
Although vascular protective effects of rosiglitazone in
some atherosclerosis models and cell culture are known,
its effects on proinflammatory gelatinase A and B
enzymes (MMP-2 and MMP-9) related to atherosclerotic
process were not thoroughly understood.
In the light of the collected data, the purpose of the
present study was to investigate the effects of PPARγ
agonist rosiglitazone on neointimal hyperplasia process




This study was approved by the Local Ethics Committee
of Dokuz Eylul University, School of Medicine. All ani-
mals received care in compliance with the principles of
laboratory animal care formulated by the National Soci-
ety for Medical Research and the Guide for the Care and
Use of Laboratory Animals. In this study, New Zealand
white rabbits of either sex (n = 13; 2,7 – 3,2 kg) were
used. Rabbits were randomly divided into two groups as
placebo and treatment groups. Throughout the 4-week
treatment period, rabbits from treatment group (n = 6)
received rosiglitazone (3 mg/kg/day, p.o.) postoperatively
[16]. Rabbits from placebo group (n = 7) received only
the vehicle (PBS; phosphate buffered saline) (2.5 ml/kg/
day, p.o.) for the same period. Throughout the 4-week
treatment period each rabbit was kept in a separate cage
and allowed to access to regular diet (standard rabbit
chow and tap water ad libitum). All animals tolerated
drug treatment well. The treatment protocol did not
affect survival rate and body weight of animals from
both groups (data not shown).Surgical procedures
Rabbits were anesthetized with intramuscular xylazine
(3 mg/kg) and ketamine (50 mg/kg). All procedures were
performed by the same surgeon using a 3.5X surgical
telescope (US PAT NO: 3273456, Designs for Vision,
Ronkonkoma, NY, USA). An oblique cervical incision
was made and the right carotid artery was surgically
accessed. Rabbits were heparinised with 100 IU/kg hep-
arin. Three minutes after heparisination, distal and prox-
imal parts were clamped and the right carotid artery was
transected. Subsequently, both ends of right carotid
artery were anastomosed in an end-to-end form using
an 8/0 polypropylene suture [17]. Then, a similar inci-
sion was made on the left contralateral carotid artery
and a segment from the left carotid artery which consti-
tuted control groups (Rosiglitazone control and PBS
control) was resected. Afterwards, the carotid arteries
were returned to their original positions and the ana-
tomic layers were closed properly. Following the oper-
ation xylazine was given intramusculary to the rabbits
for analgesia.
On the 28th postoperative day, the rabbits were sacri-
ficed using an over dose of sodium pentobarbital
(150 mg/kg). Subsequently, the anastomosed right ca-
rotid artery segment and then a segment from the
contralateral intact carotid artery as control artery were
isolated and removed. Each segment was put into a tube




After sacrification of the rabbits, tissue samples were
prepared for analysis by light microscopy and immuno-
histochemistry. Tissues were fixed in 10% neutral forma-
lin solution for 24–48 hrs. Then the samples were
embedded in paraffin and serial sections were taken onto
glass slides as in 5 μm thickness. After staining by
Orcein Light Green, they were mounted by using Entel-
lan mounting medium. Samples were examined under a
light microscope (Olympus BH2, Tokyo, Japan) and
images were transferred to the computer using a digital
video camera (Olympus DP71, Tokyo, Japan). The light
microscope was connected to an image capture system
in all groups and measurements. Multiple fields (up to
5) were selected from each section of each sample in a
systematic random pattern and images were taken and
analyzed by using software (Image Tool, Uthscsa-version
3.00 for Windows, analysis system). The images were
processed and measurements were taken in cross-
sections. Briefly, intima and media areas (μm2) were
meausured using computer-assisted image analyzer sys-
tem. Additionally, ratios of intima/media (index values)
were calculated.
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Five micrometer sample sections were incubated at 60°C
overnight then deparaffinised in xylene for 30 min. After
rehydrating by using a decreasing series of ethanols, sec-
tions were washed in distilled water for 10 min. Then
they were heated with 10 mM citrate buffer (Cat # AP-
9003-125 Labvision) for five minutes, to unmask anti-
gens. After washing in deionized water for three times
with two minutes period, sections were delineated using
a Dako pen (Dako, Glostrup, Denmark), In order to in-
hibit endogenous peroxidase activity samples were incu-
bated in 3% H2O2 for 5 min. After blocking samples
with serum solution for 30 minutes, sections were incu-
bated with primary antibody in a humid chamber for
18 h at +4°C. Anti-MMP-2 (cat. # MAB 3308, Milipore,
MA, ABD), anti-MMP-9 (Cat. # MAB 3309, Milipore,
MA, ABD) primary antibodies were used. Samples were
then incubated with anti-mouse secondary antibodies
conjugated with biotin and with streptavidin conjugated
to horseradish peroxidase for 30 min each prepared
according to kit instructions (Cat # 85–9043, Histostain-
Plus Bulk Kit Broad Spectrum, Invitrogen, Camarillo,
California, USA). They were finally incubated with 3,30
diaminobenzidine hydrochloride (DAB) (Cat # 1718096,
Roche, Oenzberg, Germany), and nuclei were counter-
stained with Mayer’s hematoxylin. All dilutions and
washing steps were performed by using phosphate buf-
fered saline (PBS), pH 7.4. Sections were dehydrated
through a graded ethanol series, cleared in xylene,
mounted in Entellan (Cat # 107961, Merck, Darmstadt,
Germany) and analyzed using a light microscope.
Appropriate positive controls were also stained.
Statistical analysis
Statistical analysis of morphometric data were performed
for drug treatments (two levels, rosiglitazone or placebo)
as between rabbit factor; and anastomosis (two levels,
present or not) as within rabbit factor with factorial ana-
lysis of variance (ANOVA). If there were interactions be-
tween the factors in ANOVA, Wilcoxon signed ranks
test and Mann Whitney U test were used for paired and
unpaired comparisons respectively.
Chi-square test was used to evaluate the statistical dif-
ference of immunohistochemical data between rosiglita-
zone and placebo group. Statistical analyses of paired
data (anastomosed vs control) from immunoscoring
were performed with Wilcoxon signed ranks test. Shown
are means ± SEM. n indicates the number of animals.
p< 0.05 was considered statistically significant.
Results
Morphometry
Intense intimal hyperplasia was observed in anasto-
mosed right arteries as compared to those in controlleft arteries in placebo group as a result of morpho-
metric examinations.
The intimal cross-sectional area (0.055 ± 0.005 μm2
control left vs 0.291 ± 0.020 μm2 anastomosed right ar-
teries) (p< 0.05) and the ratio of intimal area to medial
area (index) (0.117 ± 0.002 control vs 0.574 ± 0.013 ana-
stomosed right arteries) (p< 0.05) significantly increased
in anastomosed right arteries as compared to those in
control left arteries in placebo group (Figure 1; Figure 2;
Figure 3).
However, rosiglitazone treatment significantly decreased
the neointimal hyperplasia (0.291± 0.020 μm2 PBS group
vs 0.143± 0.027 μm2 rosiglitazone group) (p< 0.01) and
carotid artery intima/media index (0.574± 0.013 PBS
group vs 0.263± 0.0078 rosiglitazone group) (p< 0.01) in
anastomosed right arteries (Figure 2, Figure 4, Figure 3).
Medial area (0.508 ± 0.032 μm2 control left vs 0.468 ±
0.043 μm2 anastomosed right arteries) (p = 0.075) and
luminal area (0.444 ± 0.042 μm2 control left vs 0.579 ±
0.072 μm2 anastomosed right arteries) (p = 0.137) did
not change in anastomosed right arteries in the placebo
group respectively. Rosiglitazone treatment did not affect
either the medial (0.540± 0.094 μm2 PBS group vs
0.435± 0.038 μm2 rosiglitazone group) (p= 0.999) or lu-
minal cross-sectional areas (0.487± 0.085 μm2 PBS group
vs 0.545± 0.074 μm2 rosiglitazone group) (p= 0.953) re-
spectively in anastomosed right arteries.
Immunohistochemistry
Immunoscoring with MMP-2 and MMP-9 antibodies
revealed that immunopositivity for MMP-2 and MMP-9
significantly increased in anastomosed right arteries
compared to control left arteries from placebo group
(Figure 5, Table 1). However, immunoscoring for MMP-2
and MMP-9 showed that rosiglitazone treatment signifi-
cantly decreased immunopositivity for these two proteins
in anastomosed right carotid arteries compared to pla-
cebo group (Figure 6, Table 1).
Discussion
The primary reason for late bypass graft failure is
neointimal hyperplasia which occurs in response to
vascular injury [18,19]. In the present study we
showed that carotid artery anastomosis model leads
to intensive neointimal hyperplasia and increased in-
tima/media index in rabbits from placebo group con-
sistent with our previous findings [20]. However,
luminal and medial areas remained unchanged in
anastomosed arteries compared to control arteries
from placebo group as we have observed previously
in our study [20]. This latter finding may suggest
that there is a expansive vascular remodeling to
compensate narrowed luminal area and to maintain
luminal patency in anastomosed arteries. Vascular
Figure 1 Photomicrographs of orcein light green stained rabbit carotid arteries. P1: Control left artery from PBS group, P2: Anastomosed
right artery from PBS group. Star and arrow indicate intimal hyperplasia in the artery.
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arterial size and composition and also determines the de-
gree of luminal narrowing in vascular occlusive diseases,
restenosis and atherosclerosis [21,22]. Expansive vascular
remodeling notably occurs during the early period of graft
adaptation and protects luminal area [23]. However, we
have not aimed to examine remodeling process in the ar-
teries in this study. This point needs further investigation.Figure 2 Effects of anastomosis and rosiglitazone on intimal
hyperplasia in rabbit carotid arteries. White columns represent
control left, black columns represent anastomosed right carotid
arteries. n represents number of the rabbits. Placebo group (n = 7),
rosiglitazone group (n = 6). *p< 0.05 Wilcoxon signed ranks test
(control left vs anastomosed right arteries) and ++p< 0.01 Mann
Whitney U test (placebo vs rosiglitazone groups).In the present study, we also demonstrated that rosi-
glitazone inhibited neointimal hyperplasia induced by
carotid artery anastomosis model in rabbits without
affecting luminal or medial area. Previous reports have
pointed out that PPAR-γ receptor agonists could prevent
restenosis and atherosclerosis [14,24]. Similarly, in a
recent study, PPAR-γ receptor ligand rosiglitazone was
shown to decrease neointima and increase luminal area
of the vessels after balloon catheter injury in collesterol-
fed rabbits [25]. Besides, it was reported that rosiglita-
zone reduced inflammatory response and retarded
neointima progression after vascular injury in experi-
mental atherosclerosis models in mouse and rats [26].
Furthermore, rosiglitazone was demonstrated to protect
from restenosis and atherosclerosis after vascular injury
in diabetic animals, and after coronary stent location in
diabetic patients [14,24,27]. In all these models, anti-
atherosclerotic effects of rosiglitazone seem to be pleio-
tropic effects independent of their effects on glucose and
lipid metabolism [28]. However, the underlying mechan-
isms of these pleiotropic effects are not clearly known.
Therefore, we investigated the possible role of gelati-
nases and effects of rosiglitazone in our experimental
atherosclerosis model in the current study. As parallel to
our previous findings, we demonstrated semiquantita-
tively that carotid artery anastomosis model in rabbits
induces gelatinase upregulation associated with neointi-
mal hyperplasia formation [20]. We have observed in-
creasing trend of gelatinase expression in this model
previously. Unlikely, in the present study, we determined
Figure 3 Effects of anastomosis and rosiglitazone on index in
rabbit carotid arteries. White columns represent control left, black
columns represent anastomosed right carotid arteries. n represents
number of the rabbits. Placebo group (n = 7), rosiglitazone group
(n = 6). *p< 0.05 Wilcoxon signed ranks test (control left vs
anastomosed right arteries) and ++p< 0.01 Mann Whitney U test
(placebo vs rosiglitazone groups).
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semiquantitatively by scoring in rabbits [20].
Previous studies showed that unbalanced increase in
MMP activity after vascular injury may cause various
vascular pathologies including atherosclerosis, plaque
rupture, restenosis and vein graft failure [3,29,30]. In
particular, gelatinases (MMP-2 and MMP-9) were shownFigure 4 Photomicrographs of orcein light green stained rabbit carot
Anastomosed right artery from rosiglitazone group. Arrow indicates intimalto be implicated in early atherosclerotic process [29,31].
It was reported that SMC migration from intima to
media and induction of intimal hyperplasia substantially
decreased in deficiency of gelatinases [32,33]. Consistent
with our findings, recent studies demonstrated that gela-
tinases increased after vascular injury in femoral artery
wire injury model in murins, and vascular graft or collar
induced atherosclerosis models in rabbits [23,34,35].
Furthermore, increased gelatinase expression was shown
in balloon-injured Sprague–Dawley rats and aortic smooth
muscle cell culture, and also human saphenous vein
organ culture from patients undergoing coronary bypass
surgery [36,37]. Additionally, it was reported that admin-
istration of an MMP inhibitor after ballon injury or over-
expression of TIMP-1 and TIMP-2 or inhibitors of
gelatinases, respectively, inhibited neointima formation
in vivo [38-40]. Our results support all these previous
evidences concerning gelatinases and further underline
the major role of gelatinases, and significance of ECM
breakdown, promoting proliferation and migration of
vascular SMCs in atherosclerotic process.
Additionally, the increase in the levels of pro-inflam-
matory gelatinases in the anastomosed arteries points
out the presence of inflammation after vascular injury in
our model. It was known that inflammatory cytokines
such as interleukin-1 and −4 (IL-1 and IL-4) and tumour
necrosis factor-α (TNF-α) may coordinately induce gela-
tinase enzymes during progression of atherosclerosis
[30]. Moreover, growth factors such as platellet derived
growth factor (PDGF) and fibroblast growth factor-2 (FGF-
2) could interact with these cytokines [3]. Furthermore,id arteries. ROS1: Control left artery from rosiglitazone group, ROS2:
hyperplasia in the artery.
Figure 5 Representative photomicrographs of paraffin transverse sections of carotid arteries stained with MMP-2 antibody
immunohistochemically. 1:Anastomosed right carotid artery from placebo group, 2:Control left carotid artery from placebo group, 3:
Anastomosed right carotid artery from rosiglitazone-treated group, 4:Control left carotid artery from rosiglitazone-treated group. Stars show
brown stained MMP-2 immunopositive areas in the arteries. Arrows point out intima layers of the arteries.
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monocytes and differentiation to macrophages. In the
next step, monocytes and macrophages could cause
increased MMP expression [41]. All these possible
effects were shown to contribute to SMC proliferation
and migration from intima to media layer, and finally
intimal hyperplasia [3,30]. However, further studies are
necessary to elucidate the underlying molecular sig-
naling mechanisms of increased MMP expression in
this model.
As another key finding, in the current study we have
demonstrated for the first time that rosiglitazoneTable 1 İmmuno scores for MMP-2 and MMP-9 in both
anastomosed right and control left carotid arteries from
placebo (n =7) and rosiglitazone-treated (n = 6) groups
Immunoscores 0 1 2 3
MMP-2
Placebo Left 7 0 0 0
PlaceboRight* 0 0 1 6
Rosiglitazon Left 6 0 0 0
Rosiglitazon Right ++ 0 4 2 0
MMP-9
Placebo Left 7 0 0 0
Placebo Right* 0 0 2 5
Rosiglitazon Left 6 0 0 0
Rosiglitazon Right ++ 0 5 1 0significantly inhibited gelatinase expression in carotid ar-
tery anastomosis model in rabbits. Indeed, it was known
that PPAR-γ receptor agonists have important role in the
modulation of vital processes such as inflammation, prolif-
eration, differentiation and apoptosis independent of their
actions in metabolic control [6,28]. In addition, Wu et al.
demonstrated that LPS-induced gelatinase A (MMP-2) ac-
tivity was inhibited by rosiglitazone in the rat aortic endo-
thelial cells [42]. In agreement with this study, Lee et al.
showed that rosiglitazone inhibited the expression and ac-
tivity of gelatinase B (MMP-9), and vascular SMC prolif-
eration and migration through GSK-3β activation and
inhibition of NF-kB and ERK pathways in rat aortic vascu-
lar SMC culture [13]. Furthermore, Rinaldi et al. showed
that rosiglitazone diminished neointimal hyperplasia and
inflammatory events by reducing numbers and interac-
tions of inflammatory cells and also negatively regulating
the activations of inflammatory markers such as p38
MAPK, NF-B, COX-2, and HSP 47 [26]. Besides, Ling
et al. demonstrated that rosiglitazone significantly
decreased MMP-2 mRNA expression and activity, and
inhibited VSMC proliferation in cultured VSMCs which
were isolated from rat thoracic aortas [43]. Evidence from
clinical studies are similar to the data from numerous ani-
mal studies. Clinical studies showed that patients with a
history of coronary artery disease (CAD) and type 2 dia-
betes had significantly elevated serum MMP-9 levels
[44,45]. High levels of MMP-9 were reported to trigger
plaque instability and rupture [46]. However, rosiglitazone
treatment decreased MMP-9 plasma levels in patients
Figure 6 Representative photomicrographs of paraffin transverse sections of carotid arteries stained with MMP-9 antibody
immunohistochemically. 1:Anastomosed right carotid artery from placebo group, 2:Control left carotid artery from placebo group, 3:
Anastomosed right carotid artery from rosiglitazone-treated group, 4:Control left carotid artery from rosiglitazone-treated group. Stars show
brown stained MMP-9 immunopositive areas in the arteries. Arrow points out intima layer of the artery.
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the human vulnerable plaques indicates the crucial role of
MMP-9 in patients with acute coronary syndrome [46].
Therefore, the inhibitory effect of rosiglitazone on MMP-9
found in the present study may contribute to beneficial
effects of rosiglitazone on cardiovascular risk of the
patients with previous acute myocardial infarction.
Conclusion
The present study demonstrated that PPAR-γ agonist rosi-
glitazone inhibited neointimal hyperplasia and expression
of proinflammatory MMP enzymes, which have a crucial
role in initiation and progression of atherosclerosis or
restenosis in carotid artery anastomosis model in rabbits.
Our results suggest that rosiglitazone may play an
atheroprotective role via its beneficial effects on gelati-
nases (MMP-2 and −9) throughout inflammatory
process particularly in the high cardiovascular risk popu-
lation of patients with diabetes mellitus. Even though
some adverse effects of rosiglitazone treatment have
been reported recently, there is insufficient evidence of
any adverse effect on developing cardiovascular disease.
Therefore, it is still used in USA with approval of FDA.
However, further studies are necessary to elucidate the
molecular mechanism of PPARγ agonists in vascular
protection. Collected data will be useful to prove that fu-
ture PPAR agonists not only prevent atherosclerotic
events but also result in a net reduction on total cardio-
vascular incidents without any significant noncardiovas-
cular adverse effects with long-term use.Competing interests
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